Literature DB >> 31088847

Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.

Jie Deng1, Jiannan Li1, Aurelien Sarde1, J Louise Lines1, Yu-Chi Lee1, David C Qian2, Dov A Pechenick3, Richard Manivanh1, Isabelle Le Mercier1, Christopher H Lowrey4, Frederick S Varn5, Chao Cheng1,5, David A Leib1, Randolph J Noelle1, Rodwell Mabaera6.   

Abstract

Tumor hypoxia is a negative prognostic factor that is implicated in oncogenic signal activation, immune escape, and resistance to treatment. Identifying the mechanistic role of hypoxia in immune escape and resistance to immune-checkpoint inhibitors may aid the identification of therapeutic targets. We and others have shown that V-domain Ig suppressor of T-cell activation (VISTA), a negative checkpoint regulator in the B7 family, is highly expressed in the tumor microenvironment in tumor models and primary human cancers. In this study, we show that VISTA and HIF1α activity are correlated in a cohort of colorectal cancer patients. High VISTA expression was associated with worse overall survival. We used the CT26 colon cancer model to investigate the regulation of VISTA by hypoxia. Compared with less hypoxic tumor regions or draining lymph nodes, regions of profound hypoxia in the tumor microenvironment were associated with increased VISTA expression on tumor-infiltrating myeloid-derived suppressor cells (MDSC). Using chromatin immunoprecipitation and genetic silencing, we show that hypoxia-inducible factor (HIF)-1α binding to a conserved hypoxia response element in the VISTA promoter upregulated VISTA on myeloid cells. Further, antibody targeting or genetic ablation of VISTA under hypoxia relieved MDSC-mediated T-cell suppression, revealing VISTA as a mediator of MDSC function. Collectively, these data suggest that targeting VISTA may mitigate the deleterious effects of hypoxia on antitumor immunity. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31088847      PMCID: PMC6606337          DOI: 10.1158/2326-6066.CIR-18-0507

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   12.020


  42 in total

1.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository.

Authors:  Ron Edgar; Michael Domrachev; Alex E Lash
Journal:  Nucleic Acids Res       Date:  2002-01-01       Impact factor: 16.971

2.  ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments.

Authors:  Alexander Lachmann; Huilei Xu; Jayanth Krishnan; Seth I Berger; Amin R Mazloom; Avi Ma'ayan
Journal:  Bioinformatics       Date:  2010-08-13       Impact factor: 6.937

Review 3.  Hypoxia in cancer: significance and impact on clinical outcome.

Authors:  Peter Vaupel; Arnulf Mayer
Journal:  Cancer Metastasis Rev       Date:  2007-06       Impact factor: 9.264

Review 4.  Hypoxia--a key regulatory factor in tumour growth.

Authors:  Adrian L Harris
Journal:  Nat Rev Cancer       Date:  2002-01       Impact factor: 60.716

5.  HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers.

Authors:  Yoshifumi Baba; Katsuhiko Nosho; Kaori Shima; Natsumi Irahara; Andrew T Chan; Jeffrey A Meyerhardt; Daniel C Chung; Edward L Giovannucci; Charles S Fuchs; Shuji Ogino
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

Review 6.  Hypoxia-responsive transcription factors.

Authors:  Eoin P Cummins; Cormac T Taylor
Journal:  Pflugers Arch       Date:  2005-07-09       Impact factor: 3.657

7.  X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization.

Authors:  Robert L Camp; Marisa Dolled-Filhart; David L Rimm
Journal:  Clin Cancer Res       Date:  2004-11-01       Impact factor: 12.531

8.  HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment.

Authors:  Cesar A Corzo; Thomas Condamine; Lily Lu; Matthew J Cotter; Je-In Youn; Pingyan Cheng; Hyun-Il Cho; Esteban Celis; David G Quiceno; Tapan Padhya; Thomas V McCaffrey; Judith C McCaffrey; Dmitry I Gabrilovich
Journal:  J Exp Med       Date:  2010-09-27       Impact factor: 14.307

Review 9.  Inhibitory B7-family molecules in the tumour microenvironment.

Authors:  Weiping Zou; Lieping Chen
Journal:  Nat Rev Immunol       Date:  2008-06       Impact factor: 53.106

10.  Inferring activity changes of transcription factors by binding association with sorted expression profiles.

Authors:  Chao Cheng; Xiting Yan; Fengzhu Sun; Lei M Li
Journal:  BMC Bioinformatics       Date:  2007-11-16       Impact factor: 3.169

View more
  49 in total

Review 1.  Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy.

Authors:  Jackie E Bader; Kelsey Voss; Jeffrey C Rathmell
Journal:  Mol Cell       Date:  2020-06-18       Impact factor: 17.970

Review 2.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

Review 3.  VISTA: Coming of age as a multi-lineage immune checkpoint.

Authors:  M A ElTanbouly; E Schaafsma; R J Noelle; J L Lines
Journal:  Clin Exp Immunol       Date:  2020-02-04       Impact factor: 4.330

Review 4.  VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity.

Authors:  Mohamed A ElTanbouly; Walburga Croteau; Randolph J Noelle; J Louise Lines
Journal:  Semin Immunol       Date:  2019-04       Impact factor: 11.130

Review 5.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

Review 6.  Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment.

Authors:  Guangna Liu; Wei Rui; Xueqiang Zhao; Xin Lin
Journal:  Cell Mol Immunol       Date:  2021-03-30       Impact factor: 11.530

Review 7.  Tumor-related stress regulates functional plasticity of MDSCs.

Authors:  Jessica K Mandula; Paulo C Rodriguez
Journal:  Cell Immunol       Date:  2021-02-12       Impact factor: 4.868

Review 8.  Therapeutic targeting of the hypoxic tumour microenvironment.

Authors:  Dean C Singleton; Andrew Macann; William R Wilson
Journal:  Nat Rev Clin Oncol       Date:  2021-07-29       Impact factor: 66.675

9.  Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy.

Authors:  Audrey Lequeux; Muhammad Zaeem Noman; Malina Xiao; Kris Van Moer; Meriem Hasmim; Alice Benoit; Manon Bosseler; Elodie Viry; Tsolere Arakelian; Guy Berchem; Salem Chouaib; Bassam Janji
Journal:  Oncogene       Date:  2021-06-21       Impact factor: 9.867

Review 10.  Detection of Immune Checkpoint Receptors - A Current Challenge in Clinical Flow Cytometry.

Authors:  Benjamin Shibru; Katharina Fey; Stephan Fricke; André-René Blaudszun; Friederike Fürst; Max Weise; Sabine Seiffert; Maria Katharina Weyh; Ulrike Köhl; Ulrich Sack; Andreas Boldt
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.